

Citations

1. Taixiang W, Munro AJ, Guanlian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. *Cochrane Database Syst Rev* 2005;CD004540.
2. McCulloch M, See C, Shu XJ et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. *J Clin Oncol* 2006;24:419-430.
3. Upton R. *Astragalus root*. American Herbal Pharmacopoeia. Santa Cruz, CA; 1999.
4. McKenna DJ, Jones K, Hughes K. *Astragalus*. Botanical Medicines. 2nd ed. New York: Haworth Press; 2002.
5. Wagner H, Bauer R, Peigen X, Jianming C. *Radix Astragali* [Huang Qi]. Chinese Drug Monographs and Analysis. Bayer Wald: Verlag für Ganzheitliche Medizin Dr Eric Wühr GmbH; 1997;1(8):18.
6. Bensky D, Clavey S, Stogër E, Gamble A. *Ren Shen*. Chinese Herbal Medicine: Materia Medica. 3rd ed. Seattle: Eastland Press; 2004:710-714.
7. Chen J, Chen T. *Huang Qi (Radix Astragali)*. Chinese Medical Herbology and Pharmacology. City of Industry, CA: Art of Medicine Press Inc; 2004:847-853.
8. Bruneton J. *Toxic Plants Dangerous to Humans and Animals*. Hatton CK, Translator. 1st ed. Andover, UK: Intercept Ltd; 1999.
9. Zhang W-D, Chen H, Zhang C et al. Astragaloside IV from *Astragalus membranaceus* shows cardioprotection during myocardial ischemia in vivo and in vitro. *Planta Med* 2006;72:4-8.
10. Shen P, Liu MH, Ng TY et al. Differential effects of isoflavones, from *Astragalus membranaceus* and *Pueraria thomsonii*, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. *J Nutr* 2006;136:899-905.
11. Zhang YD, Shen JP, Zhu SH et al. [Effects of astragalus (ASI, SK) on experimental liver injury]. *Yao Xue Xue Bao* 1992;27:401-406.
12. Zuo L, Dong X, Sun X. The curative effects of *Astragalus membranaceus* Bunge (A6) in combination with acyclovir on mice infected with HSV-1. *Virol Sin* 1995.
13. Chu DT, Lepe-Zuniga J, Wong WL et al. Fractionated extract of *Astragalus membranaceus*, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. *J Clin Lab Immunol* 1988;26:183-187.
14. Chu D, Sun Y, Lin J et al. [F3, a fractionated extract of *Astragalus membranaceus*, potentiates lymphokine-activated killer cell cytotoxicity generated by low-dose recombinant interleukin-2]. *Zhong Xi Yi Jie He Za Zhi* 1990;10:34-36, 35.
15. Chu DT, Lin JR, Wong W. [The in vitro potentiation of LAK cell cytotoxicity in cancer and aids patients induced by F3, a fractionated extract of *Astragalus membranaceus*]. *Zhonghua Zhong Liu Za Zhi* 1994;16:167-171.
16. Wang Y, Qian XJ, Hadley HR, Lau BH. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. *Mol Biother* 1992;4:143-146.
17. Sun Y, Hersh EM, Talpaz M et al. Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. *Cancer* 1983;52:70-73.
18. Wang DC. [Influence of *Astragalus membranaceus* (AM) polysaccharide FB on immunologic function of human periphery blood lymphocyte]. *Zhonghua Zhong Liu Za Zhi* 1989;11:180-183.
19. Yoshida Y, Wang MQ, Liu JN et al. Immunomodulating activity of Chinese medicinal herbs and *Oldenlandia diffusa* in particular. *Int J Immunopharmacol* 1997;19:359-370.
20. Rou M, Renfu X. The effect of *Radix Astragali* on mouse marrow hemopoiesis. *J Tradit Chin Med* 1983;3(3):199-204.
21. Lee KY, Jeon YJ. Macrophage activation by polysaccharide isolated from *Astragalus membranaceus*. *Int Immunopharmacol* 2005;5:1225-1233.
22. Duan P, Wang Z-m. [Clinical study on effect of *Astragalus* in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2002;22:515-517.
23. Zou Y-h, Liu X-m. [Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2003;23:733-735.
24. Mills S, Bone K. *The Essential Guide to Herbal Safety*. St Louis: Churchill Livingstone; 2005.
25. Wei X, Zhang J, Li J, Chen S. *Astragalus mongholicus* and *Polygonum multiflorum*'s protective function against cyclophosphamide inhibitory effect on thymus. *Am J Chin Med* 2004;32:669-680.
26. Zhang L, Liu Y, Yu Z. [Study on the anti-herpes simplex virus activity of a suppository or ointment form of *Astragalus membranaceus* combined with interferon alpha 2b in human diploid cell culture]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 1998;12:269-271.
27. Hou YD, Ma GL, Wu SH et al. Effect of *Radix Astragali seu Hedysari* on the interferon system. *Chin Med J (Engl)* 1981;94:35-40.

Citations and Reference Literature: Astragalus

28. Zhang WJ, Wojta J, Binder BR. Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression. *J Vasc Res* 1997;34:273-280.
29. Meade TW, Ruddock V, Stirling Y et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. *Lancet* 1993;342:1076-1079.
30. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. *Lancet* 1987;2:3-9.
31. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. *Circulation* 1998;98:2241-2247.
32. Xuan W, Dong M. Effects of compound injection of *Pyrola rotundifolia* L and *Astragalus membranaceus* Bge on experimental guinea pigs' gentamicin ototoxicity. *Ann Otol Rhinol Laryngol* 1995;104:374-380.
33. Wu Y, Ou-Yang JP, Wu K et al. Hypoglycemic effect of *Astragalus* polysaccharide and its effect on PTP1B. *Acta Pharmacol Sin* 2005;26:345-352.
34. Li C, Cao L, Zeng Q. *Astragalus* prevents diabetic rats from developing cardiomyopathy by downregulating angiotensin II type 2 receptors' expression. *J Huazhong Univ Sci Technol Med Sci* 2004;24:379-384.